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Abstract
Background: The objective of this study was to identify risk factors predicting prognosis of critically ill medical
patients with advanced solid tumors in the intensive care unit (ICU).
Methods: We retrospectively analyzed all ICU unplanned medical admissions to the ICU of patients with advanced
solid cancer in Tianjin Medical University Cancer Institute and Hospital between October 1, 2012 and March 1, 2015.
Approval was obtained from the Ethical Commission of Tianjin Medical University Cancer Institute and Hospital to
review and publish information from patients’ records.
Results: One hundred and forty-one patients with full code status met the criteria for inclusion from among 813
ICU admissions. ICU mortality was 14.9 % and in-hospital mortality was 29.8 %. The major reasons for unplanned
ICU admission were respiratory failure (38.3 %) and severe sepsis or septic shock (27.7 %). The ICU mortality
in patients who required vasopressors, mechanical ventilation or renal replacement therapy for >24 h was 25,
25.9 and 40 %, respectively. The mean overall survival was 28.6 months. After adjusting for hypertension, type
of solid cancer, intervention time, need for mechanical ventilation and Acute Physiology and Chronic Health
Evaluation II score, only Sepsis-related Organ Failure Assessment (SOFA) score on day 7 of ICU treatment remained a
significant predictor of ICU mortality (adjusted odds ratio 1.612, 95 % confidence interval 1.137–2.285, P = 0.007).
Conclusions: We suggest broadening the criteria for ICU admission. The patients should be allowed an ICU
trial consisting of unlimited ICU support, including invasive hemodynamic monitoring, mechanical ventilation
and renal replacement therapy. An interdisciplinary meeting, including an ethics consultation, should be held to make
end-of-life decisions if the SOFA score on day 7 shows clinical deterioration with no available therapeutic options.
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Background
Life expectancy is rising globally and the incidence of
all-types of cancer is predicted to increase from 12.7
million new cases in 2008 to 22.2 million by 2030 [1].
An increasing number of older patients will live with
tumors and acquire life-threatening complications
from radical surgery, high-dose chemotherapy, adverse
drug events [2], increased susceptibility to infection
[3, 4] or cancer itself (such as tumor lysis syndrome,
and hypercalcemia of malignancy) [5, 6]. As a
consequence, there is an increase in critically ill pa-
tients with various types of malignancy at any stage
requiring intensive care.
Cancer treatment near the end-of-life has become
more aggressive and intensive care unit (ICU) mortality
of cancer patients has improved in recent years [7–13].
However, patients with hematological or advanced-stage
solid malignancies are still frequently denied admission
to ICUs according to current policies, even if some of
them may survive. Selection of patients inevitably leads
to undertreatment and unnecessary deaths [11].
There have been few studies about unplanned ICU
admission of critically ill patients with advanced solid
tumors in China; therefore, we conducted this study
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to establish independent risk factors for prognosis in
this patient subgroup. Three classic scoring systems
on different lengths of stay in the ICU were com-
pared for predicting prognosis. It will be helpful to
identify patients who are most likely to benefit from
critical care and decide the best time to terminate the
ICU trial and discuss a change in code status.
Methods
Study design and setting
This was a retrospective single-center observational
study conducted in the nine-bed general ICU managed
by full-time faculty members of Critical Care of Tianjin
Medical University Cancer Institute and Hospital, a
2400-bed hospital in Tianjin, China. All critically ill can-
cer patients admitted to the oncology general ICU were
evaluated between October 1, 2012 and March 1, 2015.
Patients who met all the following criteria were included:
adult patients aged ≥18 years; medical patients with a
definite diagnosis of solid cancer according to patho-
logical results obtained by surgical or microinvasive
biopsy; tumor metastasis assessed by radiography or
exfoliative cytology; life expectancy evaluated by an
oncologist as >3 months; >3 days in the ICU; and
nonpregnant women. Medical oncologists conducted
daily rounds on cancer patients in the ICU at the
time of the study. Lymphoma was not included as a
solid tumor in our study.
Epidemiological, clinical, and laboratory data col-
lected from patients’ medical records and reports in-
cluded: sex; age; time of ICU admission; chronic health
status (history of chronic heart failure, diabetes melli-
tus, hypertension, chronic renal failure or chronic bron-
chitis); type of solid cancer; metastatic sites; history of
anti-tumor therapy (such as chemotherapy, radiother-
apy and biological therapy); Karnofsky Performance
Status (KPS) at the time of admission to hospital and
ICU; cause of ICU admission; time from physiological
derangement to ICU intervention; Acute Physiology
and Chronic Health Evaluation (APACHE) II and
Sequential Organ Failure Assessment (SOFA) scores
calculated from the worst values of physiological vari-
ables in the last 24 h on days 1, 3, and 7 of the ICU
stay; presence and severity of sepsis upon ICU admis-
sion; site of infection and pathogens; therapeutic inter-
ventions during the ICU stay (use of vasopressors,
mechanical ventilation or renal replacement therapy for
>24 h); therapy after leaving ICU; length of ICU stay;
ICU and in-hospital mortality; cause of death; and over-
all survival (OS). Code status on admission and day 3
and 7 of ICU stay was also included. Permission was
obtained from the Ethical Commission of Tianjin Medical
University Cancer Institute and Hospital to review
and publish information from patients’ records. We
had all necessary written consent from any patients
involved in the study.
Patients with neutropenia (neutrophil count <500/mm3)
were excluded from the study because of the absence of a
laminar flow ward. Only insulin-treated patients were
considered to have diabetes mellitus. Chronic renal failure
was considered in patients requiring hemodialysis or peri-
toneal dialysis at the time of admission to the hospital.
Chronic heart failure was defined as New York Heart As-
sociation grades III and IV [14]. Chronic bronchitis was
defined as the presence of a productive cough or expector-
ation for >90 days a year (although on separate days) and
for >2 (consecutive) years, provided that a specific dis-
order responsible for these symptoms was not present.
Sepsis was defined as the presence of infection together
with systemic manifestations of infection. Severe sepsis
was defined as sepsis plus sepsis-induced organ dysfunc-
tion or tissue hypoperfusion. Septic shock was defined as
persistent sepsis-induced hypotension despite adequate
fluid resuscitation [15].
Statistical analysis
Statistical analyses were performed using SPSS version
19.0 (SPSS Inc., Chicago, IL, USA). Numerical variables
were described by using frequency statistics. Continuous
variables were reported as median with interquartile
range (IQR) according to the normality of distribution
verified by Kolmogorov–Smirnov test. We examined
between-group associations of demographic and clinical
variables using the χ2 test for categorical variables, inde-
pendent t test or t′ test for randomly distributed con-
tinuous variables, and the Mann–Whitney U test for
non-normally distributed continuous variables. A logistic
regression model was used to analyze the independent
risk factors for prognosis in the ICU. Odds ratio (OR)
and 95 % confidence interval (CI) were calculated using
the Cox proportional hazards model to examine the ef-
fect of multiple factors on OS. All tests were two-sided,
and P ≤ 0.05 was considered statistically significant. Vari-
ables yielding P ≤ 0.2 by univariate analysis and those
considered clinically relevant were entered in the multi-
variate analysis to estimate the independent association
of each covariate with the dependent variable.
Results
Characteristics of the study population
One hundred and forty-one patients met the inclusion
criteria from among 813 ICU admissions during the
study period. Their baseline characteristics are listed
in Table 1. The main types of cancer were stomach
cancer (23.4 %),pancreas cancer (12.8 %) and lung
cancer (10.6 %). Adenocarcinoma was the most common
pathological type (72 cases, 51.1 %). The top four meta-
static sites were lung (21 cases, 14.9 %), bone (21 cases,
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14.9 %), liver (18 cases, 12.8 %) and brain (12 cases, 8.5 %).
The major reasons for unplanned ICU admission were re-
spiratory failure (38.3 %) and severe sepsis or septic shock
(27.7 %). Forty-five patients (31.9 %) were diagnosed with
septic shock during ICU treatment. ICU mortality was
26.7 % (12 patients) and in-hospital mortality was 33.3 %
(15 patients). Sixty patients (42.6 %) were diagnosed with
severe sepsis in the ICU. ICU mortality was 10 % (six pa-
tients) and in-hospital mortality was 35 % (21 patients).
The main infections were pneumonia(66 cases, 62.9 %),
abdominal infection (27 cases, 25.7 %) and urinary tract
infection (nine cases, 8.6 %). The most common patho-
gens cultured from blood, sputum, bronchoalveolar lavage
fluid or normally sterile sites were Klebsiella pneumoniae
(21 cases, 20 %), Pseudomonas aeruginosa (15 cases,
14.3 %) and Candida tropicalis (12 cases, 11.4 %). Sixty
patients (42.6 %) required vasopressors for >24 h, 81
(57.4 %) mechanical ventilation, and 15 (10.6 %) renal re-
placement therapy.
Median time to intervention was 3 (IQR2–12) h.
Outcomes
The ICU mortality was 14.9 % (21 of 141 patients) and
the in-hospital mortality was 29.8 % (42 of 141 pa-
tients). The ICU mortality of all 813 patients and other
surgical patients during the study period was 4.3 and
2.1 %, respectively. The ICU mortality in patients who
required vasopressors, mechanical ventilation or renal
replacement therapy for >24 h was 25, 25.9 and 40 %,
respectively. The in-hospital mortality in patients who
required vasopressors, mechanical ventilation or renal
replacement therapy for >24 h was 35, 44.4 and 40 %,
respectively. The mean OS was 28.6 months. The me-
dian length of the stay in the ICU was 6 (IQR3–10)
days. Fifteen patients (10.6 %) received chemotherapy,
12 patients (8.5 %) received radiotherapy, and three
(2.1 %) received palliative surgery after discharge from
the ICU.
All of the patients lacked decision-making capacity
and had surrogates. The code status of all patients upon
ICU admission was full code. Nine patients changed
their goals on day 3 in the ICU because of worsening
medical conditions. Three surrogates (2.1 %) changed to
palliative care. Six surrogates (4.2 %) changed to sup-
portive care. They decided to withdraw treatment and
Table 1 Characteristics and outcomes of medical patients with
advanced solid cancer in the ICU
Variables N (%) or median (25th-75th percentile)
Age 63 (54–74)
Sex (male) 87 (61.7 %)
Chronic health status
Diabetes mellitus 57 (40.4 %)
Chronic heart failure 48 (34 %)
Hypertension 48 (34 %)
Chronic renal failure 0 (0)
Chronic bronchitis 6 (4.3 %)
Types of solid cancer
Stomach cancer 33 (23.4 %)
Pancreas cancer 19 (13.5 %)
Lung cancer 15 (10.6 %)
Rectal cancer 10 (7.1 %)
Colon cancer 10 (7.1)
Esophageal cancer 6 (4.3 %)
Breast cancer 6 (4.3 %)
others 42 (29.8 %)
History of antitumor therapy
Surgery 123 (87.2 %)
Chemotherapy 72 (51.1 %)
radiotherapy 18 (12.8 %)
biological therapy 6 (4.3 %)
KPS
Admit to hospital 80 (50–90)
Admit to ICU 10 (10–10)
Intervention time (hours) 3 (2–12)
Major reasons for ICU
Respiratory failure 54 (38.3 %)
Severe sepsis or septic shock 39 (27.7 %)
Acute renal failure 12 (8.5 %)
Acute heart failure 18 (12.8 %)
ICU therapeutic interventions
vasopressors 60 (42.6 %)
mechanical ventilation 81 (57.4 %)
renal replacement therapy 15 (10.6 %)
APCHE II score
Day 1 21 (18–28)
Day 3 14 (11–20)
Day 7 12 (10–15)
SOFA score
Day 1 9 (5–13)
Day 3 5 (3–9)
Day 7 4 (2–7)
Table 1 Characteristics and outcomes of medical patients with
advanced solid cancer in the ICU (Continued)
Outcomes
Length of ICU stay (days) 6 (3–10)
ICU mortality 21 (14.9 %)
In-hospital mortality 42 (29.8 %)
Overall survival (month) 17 (4–27)
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implemented do-not-resuscitate, and three died in the
ICU and the other three in a general ward. Twelve
surrogates (8.4 %) changed goals on day 6–7 to pal-
liative care after the ICU trial. Three of them died in
the ICU, and six in a general ward, and three were
discharged from hospital. Three surrogates changed to
supportive care on day 6 in the ICU. The difference
between palliative care and supportive care lied in the
fact that the latter was mainly provided by ICU team
by means of life-sustaining treatment regardless of
prognosis, while the former relied more on the nutri-
tion support and family care which could be under-
taken in the general ward or at home. Twenty-one
patients (14.9 %) died without changing code status:
15 from tumor rupture bleeding and six from cardio-
genic shock (Table 2).
Univariate analysis
Univariate comparisons of the clinical characteristics
and outcomes of survivors and non-survivors in the
ICU are presented in Table 3. Age, APACHEII score
on days 1 and 3, and SOFA score on days 1, 3 and 7
were normally distributed in survivors and non-
survivors, and verified by the Kolmogorov–Smirnov
test. Mean OS was 30.7 months in survivors and
16.7 months in non-survivors. Median time to ICU
intervention was significantly shorter in survivors
than in non-survivors (3 vs 24 h). APACHEIIand
SOFA scores on days 1, 3, and 7 of ICU treatment
were significantly higher in non-survivors. Other fac-
tors associated with higher ICU mortality were non-
stomach cancer, lung cancer, history of hypertension,
and need for mechanical ventilation.
Multivariate analysis
After adjusting for hypertension, intervention time,
need for mechanical ventilation, APACHEII score, and
other variables yielding P ≤ 0.2, only SOFA score on
day 7 of ICU treatment remained a significant pre-
dictor of ICU mortality. (adjusted OR 1.612, 95 % CI
1.137–2.285, P = 0.007).
APACHEII score on day 1 (adjusted OR 0.771, 95 %
CI 0.603–0.987, P = 0.039) was the independent risk fac-
tor of OS assessed by Cox regression analysis.
Discussion
Recently, Gruber and co-workers reported a 12-month
mortality rate of 48.3 % for long-stay ICU patients with
cancer, which means that more than half of long-stay
critically ill cancer patients survive ≥1 year [10].
Many studies have documented improved survival of
critically ill patients with cancer. Two main hypoth-
eses have been proposed to account for the decreased
mortality rate. First, the development of more potent
and targeted anti-tumor therapies, advances in the
standard strategies for determining indications and
supportive care, as well as progress in the prevention
of organ dysfunction. Cancer patients benefit from re-
duced cancer-related complications or timely inter-
vention. Second, with a deeper understanding of the
pathophysiological mechanisms in organ dysfunction,
intensive care has improved survival of critical illness
by constantly renewing strategies for survival of sep-
sis, hemodynamic monitoring, mechanical ventilation,
nutrition support, sedation, and analgesia [5, 12, 16].
The in-hospital mortality of patients with solid cancer
in our study was similar to that reported from Euro-
pean ICUs [4]. The crude ICU mortality was 14.9 %.
The ICU mortality of patients diagnosed with septic
shock was 26.7 and 10 % in those diagnosed with severe
sepsis. The ICU mortality of patients who required va-
sopressors, mechanical ventilation or renal replacement
therapy for >24 h was 25, 25.9 and 40 %, respectively.
When patients were admitted to the ICU, their APACHEII
or SOFA scores were comparable to those from most
previous studies. However, the reason why the ICU
mortality rate observed in our study mentioned above
was lower than previously 30–70 % was multifactorial
[4, 17–21], including different underlying diseases,
types of cancer, and ICU admission or discharge cri-
teria. As patients with early-stage solid tumors after
elective surgery were the main group in our ICU, the
higher mortality of cancer patients admitted for med-
ical reasons was also observed (14.9 % vs 2.1 %) [21].
As intensive care specialists, we should realize that the
endpoint of therapy in patients with advanced-stage can-
cer differs from that in patients without cancer. We
should not be concerned only with survival rate but also
with long-term survival and quality of life [6]. During
our study, in-hospital survival reached nearly 70 % after
a median 6 days in the ICU. APACHEII score on day 1
predicted poor OS, but the mean OS had already
reached 28.6 months. Thirty patients (21.3 %) had the
opportunity to receive anti-cancer treatment after ICU
treatment. Active treatment in the ICU could be more
important than many anti-cancer therapies if offers the
possibility of prolonging survival with good quality of life
for >3 months. In fact, we reached this outcome after a
median 6 days of ICU treatment.
Patients with advanced-stage cancer are frequently
denied admission to ICUs that are normally run by
non-oncologists according to current policy. Several
Table 2 Patient care decisions in the ICU
ICU days Palliative care Supportive care Intensive care
Day 3 3 (2.1 %) 6 (4.2 %) 132 (93.6 %)
Day 6–7 12 (8.4 %) 3 (2.1 %) 117 (83.0 %)
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Table 3 Characteristics and outcomes of survivors and non-survivors medical patients with advanced solid cancer in the ICU
Variables Survivor (n = 120) Non-survivor (n = 21) P value
Age 62 (54–73) 64 (55–74) 0.448
Sex (male) 72 (60 %) 15 (71.4 %) 0.692
Chronic health status
Diabetes mellitus 48 (40 %) 9 (42.9 %) 1.000
Chronic heart failure 45 (37.5 %) 3 (14.3 %) 0.396
Hypertension 27 (22.5 %) 18 (85.7 %) 0.003
Chronic renal failure 0 (0) 0 (0) -
Chronic bronchitis 6 (5 %) 0 (0) 1.000
Types of solid cancer
Stomach cancer 33 (27.5 %) 0 (0) 0.004
Pancreas cancer 19 (15.8 %) 0 (0) 0.075
Lung cancer 9 (7.5 %) 6 (28.6 %) 0.011
Rectal cancer 10 (8.3 %) 0 (0) 0.359
Colon cancer 8 (6.7 %) 2 (9.5 %) 0.644
Esophageal cancer 4 (3.3 %) 2 (9.5 %) 0.219
Breast cancer 6 (5 %) 0 (0) 0.592
others 32 (26.7 %) 10 (47.6 %) 0.066
History of antitumor therapy
Surgery 108 (90 %) 15 (71.4 %) 0.214
Chemotherapy 60 (50 %) 12 (57.1 %) 1.000
radiotherapy 15 (12.5 %) 3 (14.3 %) 1.000
biological therapy 6 (5 %) 0 (0) 1.000
KPS
Admit to hospital 80 (50–90) 40 (20–90) 0.198
Admit to ICU 10 (10–10) 10 (10–10) 0.310
Intervention time (hours) 3 (1.3–7) 24 (3–52) 0.028
Major reasons for ICU
Respiratory failure 42 (35 %) 12 (57.1 %) 0.403
Severe sepsis or septic shock 39 (32.5 %) 0 (0) 0.166
Acute renal failure 6 (5 %) 6 (28.6 %) 0.100
Acute heart failure 18 (15 %) 0 (0) 0.571
ICU therapeutic interventions
vasopressors 45 (37.5 %) 15 (71.4 %) 0.119
mechanical ventilation 60 (50 %) 21 (100 %) 0.015
renal replacement therapy 9 (7.5 %) 6 (28.6 %) 0.154
APCHE II score
Day 1 20 (17–25) 28 (26–35) 0.001
Day 3 13 (10.25–16.75) 29 (22–40) 0.000
Day 7 11.5 (10–13.75) 35 (23–41) 0.000
SOFA score
Day 1 7.5 (5–11.75) 14 (12–19) 0.002
Day 3 4.5 (2–7) 17 (10–18) 0.000
Day 7 3 (1–5) 17 (11–23) 0.000
Outcome
Length of ICU stay (days) 7 (5–10) 3 (3–8) 0.220
Overall survival (month) 18.5 (4.25–31.5) 6 (3–24) 0.324
The bold symbol: P <0.05
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studies have failed to show that diagnosis or stage of
cancer is an independent predictor of ICU mortality
[4, 9, 10, 16, 18, 19, 22–24], which was confirmed by
our logistic regression model. In other words, triage
decisions solely based on the type of cancer are thus
not justified. Intensivists sometimes need to make
quick decisions based on little or inconclusive infor-
mation. Sometimes, we may find a high hospital sur-
vival rate in a small number of patients for whom an
agreement to limit care was not achieved [25]. Thiéry
and co-workers showed 26 % survival on day 30 in
patients who were considered too ill to benefit from
ICU admission. Among the patients who were denied
ICU admission because they were felt to be too well
to benefit from admission, one quarter were subse-
quently admitted, and mortality was high (61.5 %) in
this subgroup [26]. Rapid selection depending on un-
reliable triage criteria will inevitably lead to undertreat-
ment and unnecessary death in a minority of patients [11].
The balance between reasonable hope of benefit and ex-
cessive burdens on the family or community urgently re-
quires an effective oncology critical scoring system and
risk factors analysis to broaden ICU admission criteria for
patients with cancer. APACHEIIand SOFA are the
most commonly used scoring systems in the ICU,
while Eastern Cooperative Oncology Group perform-
ance status (ECOG-PS) or KPS is often used in oncology
departments to evaluate indications for anti-tumor ther-
apy. SOFA score on day 3–6 in the ICU [4, 17–19, 23, 27]
and ECOG-PS [17, 22, 28, 29] are frequently mentioned
as significant risk factors for prognosis. In our study,
SOFA score on day 7 of ICU treatment was assessed to be
the only significant predictor of ICU mortality, which
means that poor performance on admission plays a lim-
ited role in the ICU decision-making process. In fact, the
severity of physiological derangement in the subsequent
6 days from ICU admission has the biggest impact on
ICU survival. We should receive more often than refuse
selected patients with cancer for ICU admission [16]. An
ICU trial should be offered in particular during the first
week of ICU stay [19].
The ICU trial is considered as an alternative to ICU
refusal for patients with cancer. It consists of unlimited
ICU support, including ambulatory chemotherapy,
along with mechanical ventilation and renal replace-
ment therapy, for a limited time period [5, 11, 28].
After the defined 6 days, an interdisciplinary meeting
consisting of oncologists, intensivists, nurses, psycholo-
gists, and palliative care, pain, and ethics specialists
should be held. The treatment goals should shift from
curative or supportive therapies to end-of-life care if
the reevaluation on day 7 shows clinical deterioration
with no available therapeutic options [25]. This deci-
sion to limit treatment should be based on certainty of
the benefits of the applied treatment and that it does
no harm according to the 5th International Consensus
Conference in Critical Care [30]. By strengthening the
interdisciplinary collaboration to enhance advantages
and minimize disadvantages, we could integrate hospice
and palliative care with intensive care more effectively
and efficiently. That will be the future of oncological
ICUs [31–33].
Our study had several limitations. First, this was a
retrospective study at a single cancer center. However,
to the best knowledge, it is the first report about the
prognosis and risk factors of critically ill patients with
advanced solid tumor in the ICU in China. Second, the
small size of the sample prevented us from investigating
the characteristics of critical illness in patients with dif-
ferent types of solid cancer and the effect of ambulatory
chemotherapy. Third, early identification and treatment
of critically ill cancer patients on general wards showed
no significance in our study, which was contrary to the
results from many previous studies. This is probably be-
cause the medical emergency team, which facilitates
early intervention in response to physiological instability,
was not standard in our hospital [14, 16, 18, 23]. The
intervention time in our records may have been shorter
than the real intervention time. Fourth, ethical consult-
ation is not yet ideal in our hospital. Twenty-one pa-
tients in full code status died from an emergency at the
end of life because of the lack of ethical consultation at
the time of ICU admission. Our results needs to be con-
firmed by a large prospective study.
Conclusion
In summary, an increasing number of cancer patients re-
quire intensive care. The success of active ICU treat-
ment may offer them the opportunity to prolong
survival with good quality of life and receive effective
anti-cancer therapy. According to traditional ICU admis-
sion criteria, critically ill patients with advanced solid
tumors are often deprived of the opportunity for inten-
sive care, even though >70 % of them would benefit if
admitted. We suggest broadening the criteria for ICU
admission. Patients should be allowed an ICU trial that
consists of unlimited ICU support, including invasive
hemodynamic monitoring, mechanical ventilation, and
renal replacement therapy. An interdisciplinary meeting
including ethics consultations should be held to make
clinical decisions if the SOFA score on day 7 shows clin-
ical deterioration with no available therapeutic options.
The goal of the treatment may shift from curative or
supportive therapy to end-of-life care.
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